{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:15:27Z","timestamp":1787498127012,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.thromres.2020.04.015","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T01:53:35Z","timestamp":1587002015000},"page":"124-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7257-3463","authenticated-orcid":false,"given":"Tanvi","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Lebrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2020.04.015_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report","author":"Lip","year":"2018","journal-title":"CHEST"},{"issue":"2","key":"10.1016\/j.thromres.2020.04.015_bb0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report: chest guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"CHEST"},{"key":"10.1016\/j.thromres.2020.04.015_bb0015","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.amjmed.2005.03.012","article-title":"Obesity as a risk factor in venous thromboembolism","volume":"118","author":"Stein","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.thromres.2020.04.015_bb0020","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/archinte.168.15.1678","article-title":"Overweight, obesity, and the risk of recurrent venous thromboembolism","volume":"168","author":"Eichinger","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2020.04.015_bb0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.amjcard.2010.10.018","article-title":"Relation of obesity to recurrence rate and burden of atrial fibrillation","volume":"107","author":"Guglin","year":"2011","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.thromres.2020.04.015_bb0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.thromres.2020.04.015_bb0035","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"Upreti","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.thromres.2020.04.015_bb0040","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects","volume":"47","author":"Kubitza","year":"2007","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.thromres.2020.04.015_bb0045","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.thromres.2020.04.015_bb0050","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.thromres.2020.04.015_bb0055","first-page":"1481","article-title":"Reducing the risk of stroke in patients with nonvalvular atrial fibrillation with direct oral anticoagulants. Is one of these not like the others?","volume":"9","author":"Dobesh","year":"2016","journal-title":"J Atr Fibrillation"},{"issue":"5","key":"10.1016\/j.thromres.2020.04.015_bb0060","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12325-014-0119-7","article-title":"Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results","volume":"31","author":"Cohen","year":"2014","journal-title":"Adv Ther."},{"issue":"7","key":"10.1016\/j.thromres.2020.04.015_bb0065","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/jth.13701","article-title":"Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta\u2010analysis","volume":"15","author":"Boonyawat","year":"2017","journal-title":"J Thromb Haemost."},{"issue":"38","key":"10.1016\/j.thromres.2020.04.015_bb0070","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/eurheartj\/ehw124","article-title":"The \u2018obesity paradox\u2019 in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial","volume":"37","author":"Sandhu","year":"2016","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.thromres.2020.04.015_bb0075","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.amjcard.2017.03.028","volume":"119","author":"Balla","year":"2017","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2020.04.015_bb0080","first-page":"739","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to bodyweight. A sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"Di Nisio","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"129","key":"10.1016\/j.thromres.2020.04.015_bb0085","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2020.04.015_bb0090","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/STROKEAHA.116.015984","article-title":"There an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials","volume":"48","author":"Proietti","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2020.04.015_bb0095","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2020.04.015_bb0100","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2020.04.015_bb0105","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH16-02-0087","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"Di Nisio","year":"2016","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.04.015_bb0110","first-page":"1199","article-title":"Relationship between body mass index and outcomes in 21,028 patients with atrial fibrillation treated with edoxaban or warfarin in ENGAGE AF-TIMI 48 trial","volume":"37","author":"Boriani","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2020.04.015_bb0115","first-page":"1111","article-title":"The use of dabigatran according to body mass index: the RE-LY experience","volume":"35","author":"Ezekowitz","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2020.04.015_bb0120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11239-019-01857-2","article-title":"Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review","volume":"48","author":"Netley","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.thromres.2020.04.015_bb0125","article-title":"Investigation of direct-acting oral anticoagulants and the incidence of venous thromboembolism in patients weighing \u2265120 kg compared to patients weighing <120 kg","author":"Aloi","year":"2019","journal-title":"J. Pharma. Pract."},{"key":"10.1016\/j.thromres.2020.04.015_bb0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2018.03.060","article-title":"Impact of BMI on clinical outcomes of NOAC therapy in daily care - results of the prospective Dresden NOAC Registry (NCT01588119)","volume":"262","author":"Titt","year":"2018","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.thromres.2020.04.015_bb0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest."},{"key":"10.1016\/j.thromres.2020.04.015_bb0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"10.1016\/j.thromres.2020.04.015_bb0145","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.5152\/AnatolJCardiol.2015.6532","article-title":"A review of the fixed dose use of new oral anticoagulants in obese patients: is it really enough?","volume":"15","author":"Guler","year":"2015","journal-title":"Anatol. J. Cardiol."},{"key":"10.1016\/j.thromres.2020.04.015_bb0150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.thromres.2020.04.015_bb0155","series-title":"Pradaxa [Package Insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc","year":"2010"},{"key":"10.1016\/j.thromres.2020.04.015_bb0160","series-title":"Xarelto [Package Insert]. Leverkusen, Germany: Bayer Pharma AG","year":"2011"},{"key":"10.1016\/j.thromres.2020.04.015_bb0165","series-title":"Eliquis [Package Insert]. Princeton, NJ: Bristol-Myers Squibb Company","year":"2012"},{"issue":"2","key":"10.1016\/j.thromres.2020.04.015_bb0170","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1060028018796604","article-title":"Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation","volume":"53","author":"Kido","year":"2019","journal-title":"Ann Pharmacother."},{"issue":"4","key":"10.1016\/j.thromres.2020.04.015_bb0175","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1060028019886092","article-title":"Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight","volume":"54","author":"Perales","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"21","key":"10.1016\/j.thromres.2020.04.015_bb0180","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","article-title":"Management and outcomes of major bleeding during treatment with dabigatran or warfarin","volume":"128","author":"Majeed","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.thromres.2020.04.015_bb0185","unstructured":"Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) J Am Coll Cardiol. 2014;63(9):891\u2013900."},{"issue":"20","key":"10.1016\/j.thromres.2020.04.015_bb0190","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes","volume":"63","author":"Hylek","year":"2014","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"10.1016\/j.thromres.2020.04.015_bb0195","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.amjmed.2018.10.008","article-title":"Concomitant use of direct oral anticoagulants with antiplatelet agents and the risk of major bleeding in patients with nonvalvular atrial fibrillation","volume":"132","author":"Douros","year":"2019","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.thromres.2020.04.015_bb0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.urology.2017.11.023","article-title":"Incidence of visible hematuria among antithrombotic agents: a systematic review of over 175,000 patients","volume":"114","author":"Bhatt","year":"2018","journal-title":"Urology"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2020.04.015_bb0205","first-page":"1105","article-title":"Apixaban is safe and effective in morbidly obese patients: a retrospective analysis of 390 patients with BMI \u226540","volume":"130","author":"Billett","year":"2017","journal-title":"Blood Dec"},{"key":"10.1016\/j.thromres.2020.04.015_bb0210","series-title":"Hospital Practice","article-title":"Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients","author":"Kalani","year":"2019"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820301316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820301316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:42:53Z","timestamp":1758735773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384820301316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":42,"alternative-id":["S0049384820301316"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.04.015","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}